Peninsula cell therapy company’s CEO resigns as FDA raises manufacturing questions

Maria Fardis, who turned a little-known cell therapy company to the cusp of an approved treatment for solid tumors, resigned after regulators said they need more information about the manufacturing process behind Iovance Biotherapeutics Inc.'s drug. The San Carlos company (NASDAQ: IOVA) shed nearly 40% of its value...

Click to view original post